CD-ROM

Hepatitis co-infections: (including HBV, HCV)

Presentation type		Track	Abstract category	Text
All Oral abstracts Poster Discussions Poster Exhibition CD-ROM		All A B C D	All Acute and early infection Acute and early infection and management of patients with acquired viral resistance Adherence in adults Adherence in children and adolescents Ageing AIDS related malignancies (KS, lymphoma, cervical and anal carcinoma) including HHV8 infection Animal Models Animal models of transmission, disease resistance and progression Antibody based vaccines Antiretroviral Therapies (strategic categories apply to resource rich and constrained settings) in Children and Adolescents Antiretroviral therapy,clinical trials and cohorts Antiretroviral treatment of people living with HIV for prevention Approaches to counselling and testing in children and caregivers Behavioural surveillance Bioinformatic analysis in drug resistance Bioinformatics analysis of viral diversity in natural history Blood, organ and tissue safety and nosocomial transmission Cellular immunity based vaccines Clinical trials Cohort studies Complementary and traditional medicines and the role of traditional healers in therapy Complications of Anti-Retroviral Therapy and Adherence in Adults and Children Correlates of immune protection Diagnosis of HIV disease Diagnostic Tools for the Immunological and Virological Monitoring of HIV Infection Disease burden – morbidity/mortality Epidemiology of HIV in people who use drugs Epidemiology of sexually transmitted infections (STI) and HIV Estimating the need for HIV treatment Estimating the size of HIV-infected and most at risk population Ethical issues in epidemiological research First line therapy Harm reduction, including reduction of unsafe injecting and other approaches Hepatitis co-infections: (including HBV, HCV) HIV counselling, testing and diagnostic strategies HIV diversity and epidemiology HIV Pathogenesis/Immune Function and Dysfunction HIV Pathogenesis/Latency and Viral Reservoirs HIV superinfections HIV Surveillance, Monitoring and Evaluation HIV tropism, dynamics and fitness HIV-1 and HIV-2 co-infections HIV-2 Host genetics of resistance and susceptibility Immune reconstitution disorders / IRIS Impact of nutrition Innate immunity responses and function in natural history of HIV infection Malaria Male and female condoms and other physical barriers Male circumcision Management of late presenters Measuring and modelling the effect and impact of other HIV prevention interventions Measuring and modelling the effect and impact of PMTCT Measuring and modelling the impact of the HIV epidemic Mechanisms of T cell depletion and dysfunction Methodological Issues and Capacity-Building in Epidemiology and Prevention Research Microbicides Monitoring and evaluation (other) Monitoring and evaluation of HIV prevention, care and treatment Mother to child transmission Mucosal immunity/defenses: responses and dysfunction Mucosal transmission Mycobacteria and TB Natural history, progression and survival Neurologic and psychiatric manifestations, including neurocognitive disorders New HIV testing and diagnostic strategies New monitoring strategies including rapid tests Non pathogenic models of SIV Non-AIDS related co-morbidities (e.g. diabetes, hypertension etc) Non-AIDS related malignancies Novel animal models for vaccine and inhibitor development Novel assays of immune responses Novel Treatment and Prevention Strategies Novel vectors and strategies Nucleic acid based HIV and SIV therapies Opportunistic infections (excluding mycobacterial) Other adverse reactions and complications of ARV therapy Other bacterial infections and malaria and parasitic infections Other complications Other Therapies Paediatric surveillance of HIV Pharmacogenomics Pharmacology, pharmacokinetics, drug formulations Population-based surveys with HIV testing Preclinical development of microbicides Pre-exposure and post-exposure prophylaxis Prevention addressing gender inequalities Prevention for men who have sex with men (MSM) Prevention for people living with HIV Prevention for people who use drugs Prevention for the general population Prevention in institutional settings e.g. workplace, school, prison, military Prevention of mother-to-child transmission Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis and HPV, co-trimoxazole prophylaxis and IPT Research designs in epidemiology Sexually transmitted infections (STI) Simplification strategies (induction/maintenance and use of bPI monotherapy) STI prevention and control Surveillance of HIV (Youth and Adults) Surveillance systems and methods Switch studies Therapy for the heavily pre-treated patient Track B - Clinical Sciences Track C: Epidemiology and Prevention Sciences Transmission and Early Infection Tuberculosis Viral determinants of SIV pathogenesis Viral fitness and tropism assays, utility and application in clinical practice Viral resistance testing in clinical trials and practice Virus-specific cellular immunity When to start therapy
Late breakers only

Posters with this symbol have been selected by the Scientific Programme Committee for distinction based on merit.

Posters with this symbol have an e-Poster available.

CDB044 Abstract Role of antidepressants in relieving the impact of fatigue in HIV-HCV co-infected patients: results from the HEPAVIH French cohort (ANRS Co13) L. Michel1,2,3, V. Villes4,5,6, F. Dabis7, B. Spire4,5,6, M. Winnock7, M.-A. Loko7, I. Poizot-Martin8, M.-A. Valantin9, P. Bonnard10, M. Bentata11, D. Salmon-Céron12, M.-P. Carrieri4,5,6 1INSERM U669, Paris, France, 2Université Paris-Sud and Université Paris Descartes, UMR-S0669, Paris, France, 3AP-HP, Hôpital Emile Roux, Centre de Traitement des Addictions, Limeil-Brévannes, France, 4INSERM, U912 (SE4S), Marseille, France, 5Université Aix Marseille, IRD, UMR-S912, Marseille, France, 6ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille, France, 7INSERM U897, Bordeaux, France, 8CHU Sainte Marguerite, Marseille, France, 9CHU de la Pitié Salpétrière, Paris, France, 10Hôpital Tenon, Paris, France, 11Service de Médecine Interne, Hôpital Avicenne, Bobigny, France, 12Hôpital Cochin Port-Royal, Paris, France CDB045 Abstract HIV/HBV and HIV/HCV co-infection in Burkina Faso, West Africa F. Buelli1,2, E. Focà1,2, S. Odolini1,2, V. Pietra1,2,3, J. Simporé4,5, S. Caligaris1,2, M. Pinotti2,6, S. Guarisco2,6, F. Schumacher2,6, A. Plebani6, F. Castelli1,2 1University of Brescia, Institute for Infectious and Tropical Diseases, Brescia, Italy, 2Medicus Mundi Italia, Brescia, Italy, 3Hôpital St Camille, Nanoro, Burkina Faso, 4Centre Médical St Camille, Ouagadougou, Burkina Faso, 5Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso, 6University of Brescia, Pedriatric Clinic, Brescia, Italy CDB046 Abstract Acute hepatitis C is not associated with abnormal fibroscan readings P. Holmes, M. Bower, E. Low, B. Gazzard, M. Nelson Chelsea and Westminster Hospital NHS Foundation Trust, HIV/GUM Medicine, London, United Kingdom CDB047 Abstract Incidence of hepatitis B and C viral infection among HIV-infected patients initiating antiretroviral therapy at the University Teaching Hospital in Lusaka, Zambia K.C. Kapembwa1, S. Lakhi1, J. Goldman2, Y. Banda2, B. Chi2 1University Teaching Hospital, Internal Medicine, Lusaka, Zambia, 2Center for Infectious Disease Research Zambia, Lusaka, Zambia CDB048 Abstract Usefulness of the AST to platelet ratio index (APRI) for the prediction of cirrhosis in HIV/HCV coinfected patients P. Marti-Belda1, C. Quereda1, J.L. Casado1, A. Moreno1, M.J. Perez-Elias1, F. Dronda1, A. Moreno2, S. Moreno1 1Ramón y Cajal Hospital, Infectious Diseases, Madrid, Spain, 2Ramón y Cajal Hospital, Pathology, Madrid, Spain CDB049 Abstract Usefulness of a non invasive marker of liver fibrosis to establish the risk of HAART-associated hepatotoxicity in HIV/HCV co-infected patients J.L. Casado, C. Quereda, J. Moya, P. Marti-Belda, B. Hernandez-Novoa, A. Moreno, M.J. Perez-Elias, F. Dronda, S. Moreno Ramón y Cajal Hospital, Infectious Diseases, Madrid, Spain CDB050 Abstract The Cedar Project: gender differences in hepatitis C virus (HCV) infection among aboriginal young people who use injection drugs in two Canadian cities P. Spittal1,2, S. Patel1,2, A. Moniruzzaman1,2, V. Thomas3, K. Patterson4, M. Schechter1,2, For the Cedar Project Partnership 1University of British Columbia, School of Population and Public Health, Vancouver, Canada, 2Centre for Health Evaluation and Outcome Sciences, Vancouver, Canada, 3Cedar Project, Project Coordinator, Prince George, Canada, 4BC Ministry of Health, Aboriginal Health, Victoria, Canada CDB051 Abstract Role of transforming growth factor-β1 on liver fibrosis in HIV patients with chronic hepatitis C N. Rallon1, P. Barreiro1, V. Soriano1, M. Lopez1, J. García-Samaniego2,3, P. Labarga1, M. Romero2,3, J. González Lahoz1, J.M. Benito1 1Hospital Carlos III, Infectious Diseases Department, Madrid, Spain, 2Hospital Carlos III, Hepatology, Madrid, Spain, 3CIBEREHD, Madrid, Spain CDB052 Abstract Characteristics of HIV patients newly diagnosed with compensated liver cirrhosis by non-invasive techniques P. Tuma, L. Martin-Carbonero, P. Barreiro, E. Vispo, J. Medrano, P. Labarga, V. Soriano Hospital Carlos III, Infectious Disease, Madrid, Spain